Prevention of Microbial Contamination - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prevention of Microbial Contamination
A holistic approach to establishing robust control measures.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 62-65

References

1. D. Ariely, "On Empathy and Emotion," in Why We Respond to One Person Who Needs Help but Not to Many (HarperCollins Publishers, New York, NY, 2010), pp. 237-256.

2. Gregory Roumeliotis, "FDA Report Sheds Light on Chiron's Problems," http://Outsourcing-Pharma.com/, (July 2006).

3. John George, Phil. Bus. Jrnl. (January 2011).

4. R.M. Donlan, Emerg. Infect. Dis. 7 (2) 277–281 (2011).

5. J. Glausiusz, "Your Body is a Planet," Disc. Mag. (June 2007).

6. USP 32–NF 27 General Chapter <1072>, "Disinfectants and Antiseptics" (USP, Bethesda, MD), pp. 576–580.

7. European Commission, "Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products," Rev., Guidelines to Good Manufacturing Practice (Brussels, Belgium, Nov. 2008).

8. GMP Trends #734, (GMP Trends, Inc., Boulder, CO, Aug. 15, 2007), p. 2.

9. S.S. Block, "Fundamental Principles of Activity" in Disinfection, Sterilization, and Preservation (Lippincott Williams & Wilkins, Philadelphia, PA, 5th ed., 2001), pp. 31–79.

10. GMP Trends #631 (GMP Trends, Inc., Boulder, CO, May 1, 2003), p. 4.

11. FDA, Warning Letter NEW-16-08 W, Issued Jul. 2, 2008, http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048221.htm, accessed Jan. 19, 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here